Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Martin Welschof Ph.D. | President & CEO | 5.17M | -- | 1961 |
| Mr. Stefan Ericsson M.B.A. | Chief Financial Officer | -- | -- | 1963 |
| Ms. Marie Moores M.Sc., R.G.N. | Chief Operating Officer | -- | -- | -- |
| Mr. Kristoffer Rudenholm Hansson | Senior Vice President of Technical Operations | -- | -- | 1974 |
| Mr. Björn Frendéus | Chief Scientific Officer | 2.35M | -- | 1973 |
| Ms. Cecilia Hofvander | Senior Director of Investor Relations | -- | -- | 1967 |
| Dr. Andres McAllister | Chief Medical Officer | -- | -- | 1956 |
| Ms. Ingrid Teige | Head of Preclinical Research | -- | -- | -- |
| Ms. Sylvie Ryckebusch | Chief Business Officer | -- | -- | -- |
| Dr. Ingunn Munch Lindvig | Senior Vice President of Regulatory Affairs | -- | -- | -- |
BioInvent International AB (publ)
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 115
Description
BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. Its drug candidates are BI-1808 is in phase 2 clinical trial and BI-1910 in phase 1 clinical trial for solid tumors targeting Tumor necrosis factor receptor-2 (TNFR2); BI-1206/rituximab in phase 2 clinical trial for the treatment of non-Hodgkin's lymphoma; BI-1206/pembrolizumab and BI-1607/trastuzumab in phase 1 clinical trial to treat solid tumors targeting FCYRIIB; and BT-001 in phase 1 clinical trial for the treatment of solid tumors targeting Cytotoxic T lymphocyte-associated protein-4. The company has a partnership and collaboration with Transgene to develop BT-001 oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck to evaluate BI-1206, BI-1808, and BT-001 in combination with Keytruda; and licensing agreement with CASI pharmaceuticals for BI-1206. The company was incorporated in 1996 and is based in Lund, Sweden.
Corporate Governance
Upcoming Events
February 20, 2025 at 7:00 AM UTC - February 24, 2025 at 7:00 AM UTC
BioInvent International AB (publ) Earnings Date
Recent Events
Recent Events Information Not Available